DeepMed Research

United Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $15.5B

Website: http://www.unither.com

Clinical Trials

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil Inhalation Powder

First Posted Date: 2019-05-15

Last Posted Date: 2024-11-01

Lead Sponsor: United Therapeutics

Target Recruit Count: 51

Registration Number: NCT03950739

Locations: 🇺🇸
Ascension / St. Vincent's Lung Institute, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
University of South Florida Center for Advanced Lung Disease, Tampa, Florida, United States

and more 13 locations

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Non-Treprostinil PAH Medications
Drug: Treprostinil

First Posted Date: 2019-03-25

Last Posted Date: 2021-03-16

Lead Sponsor: United Therapeutics

Target Recruit Count: 43

Registration Number: NCT03888365

Locations: 🇺🇸
Cedars-Sinai Medical Center, Beverly Hills, California, United States
🇺🇸
The Mount Sinai Hospital, New York, New York, United States
🇺🇸
Pulmonary Health Physicians, PC, Fayetteville, New York, United States

and more 7 locations

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Phase 1

Terminated

Conditions: Bronchopulmonary Dysplasia

Interventions: Biological: UNEX-42
Biological: Phosphate-buffered saline

First Posted Date: 2019-02-28

Last Posted Date: 2021-10-12

Lead Sponsor: United Therapeutics

Target Recruit Count: 3

Registration Number: NCT03857841

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 3 locations

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Phase 3

Terminated

Conditions: Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension

Interventions: Drug: Inhaled treprostinil solution

First Posted Date: 2019-01-07

Last Posted Date: 2023-12-18

Lead Sponsor: United Therapeutics

Target Recruit Count: 41

Registration Number: NCT03794583

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

and more 27 locations

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Phase 3

Conditions: PAH
Familial Primary Pulmonary Hypertension
Hypertension, Pulmonary
Respiratory Tract Disease
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Hypertension
Cardiovascular Diseases
Connective Tissue Diseases
Vascular Diseases

Interventions: Drug: Ralinepag

First Posted Date: 2018-09-25

Last Posted Date: 2025-04-20

Lead Sponsor: United Therapeutics

Target Recruit Count: 1000

Registration Number: NCT03683186

Locations: 🇺🇸
Oregon Clinic-Pulmonary West, Portland, Oregon, United States
🇦🇷
Cardiologia Palmero, Caba, Argentina
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 206 locations

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Phase 3

Recruiting

Conditions: Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Pulmonary Arterial Hypertension
Hypertension
Familial Primary Pulmonary Hypertension
PAH
Connective Tissue Diseases
Lung Diseases

Interventions: Drug: Placebo
Drug: Ralinepag

First Posted Date: 2018-08-13

Last Posted Date: 2025-04-20

Lead Sponsor: United Therapeutics

Target Recruit Count: 1000

Registration Number: NCT03626688

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

and more 211 locations

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Phase 4

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil

First Posted Date: 2018-04-13

Last Posted Date: 2023-08-07

Lead Sponsor: United Therapeutics

Target Recruit Count: 36

Registration Number: NCT03497689

Locations: 🇺🇸
UPMC Presbytarian Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
St. Vincent Medical Group, Indianapolis, Indiana, United States
🇺🇸
University of Cincinnati Health, Cincinnati, Ohio, United States

and more 8 locations

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Terminated

Conditions: Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease

Interventions: Drug: Inhaled treprostinil solution
Drug: Placebo solution

First Posted Date: 2018-04-12

Last Posted Date: 2023-11-24

Lead Sponsor: United Therapeutics

Target Recruit Count: 188

Registration Number: NCT03496623

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States
🇺🇸
St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States

and more 73 locations

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Biological: Dinutuximab
Drug: Irinotecan
Drug: Topotecan

First Posted Date: 2017-03-31

Last Posted Date: 2020-12-09

Lead Sponsor: United Therapeutics

Target Recruit Count: 483

Registration Number: NCT03098030

Locations: 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇭🇺
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Semmelweis Tagkórház, Tüdőgyógyászati Osztály, Miskolc, Hungary

and more 217 locations

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Phase 3

Withdrawn

Conditions: Pulmonary Hypertension Associated With Sickle Cell Disease

Interventions: Drug: Oral Treprostinil
Drug: Placebo

First Posted Date: 2017-02-16

Last Posted Date: 2017-04-11

Lead Sponsor: United Therapeutics

Registration Number: NCT03055234

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy